Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients

摘要: Study Type – Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does study add? Different tools allow individual estimation various endpoints in patients with prostate cancer. The Cancer Prostate Risk Assessment (CAPRA) score is an easy to calculate prediction tool, based a large population database. However, little about performance this tool European patients. The data obtained present demonstrate differences tumour characteristics between initial development cohort from USA. concordance index CAPRA scores for predicting biochemical recurrence metastatic was 76.2 78.5, respectively, patients. Therefore, also allows reliable examined patients. OBJECTIVES • To assess ability Score (BCR) (MR) by using cancer. • The initially developed treated community-based hospitals USA risk different clinical endpoints, without incorporating surgical margin status. PATIENTS AND METHODS • BCR rates were studied 2937 who underwent radical prostatectomy tertiary referral centre after mean (median, range) follow-up 49 (56, 12–220) months. • The association pathological features analyzed Kaplan–Meier, proportional hazard logistic regressions analyses. • Graphical representation assessed calibration both endpoints. RESULTS • Compared cohort, worse lower overall positive rate (17.2% vs 32.4%) detected cohort. • Overall, 530 (18.4%) 58 (1.9%) BCR MR. Increasing related less favourable higher rates. • For example, 5-year markedly at extremes 0–1 ≥8 (9.2% 70.8% 0.7% 16.4%, respectively). • The respectively. CONCLUSIONS • Despite respect outcomes achieved, shows generalizability score. • Specifically, precise identification those are high